학술논문
752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations
Document Type
Abstract
Author
Source
In Annals of Oncology September 2020 31 Supplement 4:S584-S585
Subject
Language
ISSN
0923-7534